Skip to main content
SpringerLink
Log in

Metastatic pattern and response to endocrine therapy in human breast cancer

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The effect of endocrine therapy in 465 postmenopausal patients with advanced breast cancer who entered four consecutive, randomized trials has been related to the site of the metastases. Patients received either tamoxifen (T) alone or T in combination with medroxyprogesterone acetate, diethylstilbestrol, halotestin, or aminoglutethimide. The overall response rate was 40%. Responses were most frequently seen in patients with metastases in soft tissue, and the duration of response to endocrine therapy in these patients was longer than for those with metastases in bone or viscera (p<0.00001). In addition, the response rate was inversely correlated with the number of main metastatic sites in patients with soft tissue metastases, whereas the response rate was not associated with the number of metastatic sites in patients with metastases in bone and viscera. Survival after first recurrence was significantly longer in responding patients with soft tissue lesions compared to those with recurrence in bone or viscera. In contrast, survival after first recurrence was identical in patients with nonresponding disease, irrespective of dominant site of metastases.

The outcome of endocrine therapy depends partially upon the dominant site of metastases. This may reflect a difference in biological characteristics of human breast cancer tumor cells that metastasize to different sites.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sainsbury JRC, Farndon JR, Sherbet GV, Harris AL: Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet i: 364–366, 1985

    Google Scholar 

  2. Paterson AHG, Szafran O, Lees AW, Hanson J: Prognostic factors at presentation and their relevance to the natural history of breast cancer. Rev Endocrine-Related Cancer, suppl 14: 35–39, 1984

    Google Scholar 

  3. Silvestrini R: Cell kinetic and ER assays in breast cancer. Rev Endocrine-Related Cancer 18: 15–19, 1984

    Google Scholar 

  4. Howell A, Bush H, George WD, Howat JMT, Crowther D, Sellwood RA, Rubens RD, Hayward JL, Bulbrook RD, Fentiman IS, Chaudary M: Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Lancet ii: 307–311, 1984

    Google Scholar 

  5. Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M, Rasmussen BB: Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet i: 16–19, 1985

    Google Scholar 

  6. Howat JMT, Harris M, Swindell R, Barnes DM: The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Br J Cancer 51: 263–270, 1985

    PubMed  Google Scholar 

  7. Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap H-Y, Gutterman JU, Blumenschein GR: Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39: 1552–1562, 1979

    PubMed  Google Scholar 

  8. Roos E, Dingemans KP: Mechanisms of metastasis. Biochim Biophys Acta 560: 135–166, 1979

    PubMed  Google Scholar 

  9. Singhakowinta A, Potter HG, Samal B, Brooks SC, Vaitkevicius VK: Estrogen receptors and natural course of breast cancer. Ann Surg 183: 84–88, 1976

    PubMed  Google Scholar 

  10. Stewart JF, King RJB, Sexton SA, Millis RR, Rubens RD, Hayward JL: Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer 17: 449–453, 1981

    PubMed  Google Scholar 

  11. Campbell FC, Blamey RW, Elston CW, Nicholson RI, Griffiths K, Haybittle JL: Oestrogen-receptor status and sites of metastasis in breast cancer. Br J Cancer 44: 456–459, 1981

    PubMed  Google Scholar 

  12. Lippman ME, Allegra JC, Thompson EB, Simon R, Barlock A, Green L, Huff KK, DO HMT, Aitken SC, Warren R: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298: 1233–1238, 1978

    Google Scholar 

  13. de la Monte SM, Hutchins GM, Moore GW: Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma. Amer J Med 76: 11–17, 1984

    Google Scholar 

  14. Rosen PP, Menendez-Botet CJ, Urban JA, Fracchia A, Schwartz MK: Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer. Cancer 39: 2194–2200, 1977

    PubMed  Google Scholar 

  15. Holdaway IM, Bowditch JW: Variation in receptor status between primary and metastatic breast cancer. Cancer 52: 479–485, 1983

    PubMed  Google Scholar 

  16. Paridaens R, Sylvester RJ, Ferrazzi E, Legros N, Leclercq G, Heuson JC: Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer 46: 2889–2895, 1980

    PubMed  Google Scholar 

  17. Fernandez MD, Alaghband-Zadeh J, Burn JI: Quantitative oestrogen and progesterone receptor values in primary breast cancer and predictability of response to endocrine therapy. Clin Oncol 9: 245–250, 1983

    PubMed  Google Scholar 

  18. Rose C, Thorpe SM, Løber J, Daenfeldt JL, Palshof T, Mouridsen HT: Therapeutic effect of tamoxifen related to estrogen receptor level. In: Henningsen B, Linder F, Steichele C (eds): Endocrine Treatment of Breast Cancer. Springer-Verlag, Berlin-Heidelberg-New York, 1980, pp 134–141. (Recent Results in Cancer Research).

    Google Scholar 

  19. Rose C, Theilade K, Boesen E, Salimtschik M, Dombernowsky P, Brunner N, Kjaer M, Mouridsen HT: Treatment of advanced breast cancer with tamoxifen: Evaluation of the dose-response relationship at two dose levels. Breast Cancer Res Treat 2: 395–400, 1982

    Google Scholar 

  20. Mouridsen HT, Salimtschik M, Dombernowsky P, Gelshoj K, Palshof T, Rorth M, Daehnfeldt JL, Rose C: Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women. In: Mouridsen HT, Palshof T (eds): Breast Cancer — Experimental and Clinical Aspects. Pergamon Press, Oxford and New York, 1980, pp 107–110

    Google Scholar 

  21. Mouridsen HT, Ellemann K, Mattsson W, Palshof T, Daehnfeldt JL, Rose C: Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 63: 171–175, 1979

    PubMed  Google Scholar 

  22. Rose C, Kamby C, Mouridsen HT, Bastholt L, Brincker H, Skovgaard-Poulsen H, Andersen AP, Loft H, Dombernowsky P, Andersen KW: Combined endocrine treatment of postmenopausal patients with advanced breast cancer. Breast Cancer Res Treat 7 (suppl): 45–50, 1986

    PubMed  Google Scholar 

  23. Rose C, Kamby C, Mouridsen HT, Bastholt L, Brincker H, Skovgaard-Poulsen H, Andersen AP, Loft H, Dombernowsky P on behalf of DBCG: Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone vs. tamoxifen plus fluoxymesterone. (Abstract, submitted to Am Assoc Clin Oncol 1986)

  24. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13: 89–94, 1977

    Google Scholar 

  25. Peto R, Pike MC, Armitage P, Breslow E, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1–39, 1977

    PubMed  Google Scholar 

  26. Maass H, Jonat W: Site factor affecting response of metastases. In: Stoll BA (ed): Systemic control of breast cancer, ch. 9, pp 188–203, vol. 4 in the series: New Aspects of Breast Cancer, William Heinemann Medical Books, London 1980

    Google Scholar 

  27. Campbell FC, Blamey RW, Elston CW, Morris AH, Nicholson RI, Griffiths K, Haybittle JL: Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet ii: 1317–1319, 1981

    Google Scholar 

  28. Qazi R, Chuang J-L, Drobyski W: Estrogen receptors and the pattern of relapse in breast cancer. Arch Intern Med 144: 2365–2367, 1984

    PubMed  Google Scholar 

  29. Budd GT: Estrogen receptor profile of patients with breast cancer metastatic to bone marrow. J Surg Oncol 24: 167–169, 1983

    PubMed  Google Scholar 

  30. Kamby C, Rose C, Iversen H, Holm NV, Andersen KW, Thorpe SM: Pattern of metastases in human breast carcinoma in relation to estrogen receptor status. Anticancer Res 6: 107–112, 1986

    PubMed  Google Scholar 

  31. Hahnel R, Woodings T, Vivian AB: Prognostic value of estrogen receptors in primary breast cancer. Cancer 44: 671–675, 1979

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology ONA, The Finsen Institute, 49, Strandboulevarden, DK-2100, Copenhagen Ø, Denmark

    Claus Kamby & Carsten Rose

Authors
  1. Claus Kamby
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carsten Rose
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kamby, C., Rose, C. Metastatic pattern and response to endocrine therapy in human breast cancer. Breast Cancer Res Tr 8, 197–204 (1986). https://doi.org/10.1007/BF01807332

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01807332

Keywords

Search

Navigation